biotech / news / / Barchart
Boston Scientific (BSX) has become quite toxic for shareholders.
Boston Scientific stock fell over 37% in 2024, erasing late-2023 gains.
KEY POINTS
- The $374-per-share Penumbra acquisition faces integration friction and caused shareholder valuation concerns.
- Boston Scientific is losing market share in pulsed field ablation due to increased competition.
- A Markovian induction model suggests a 54.1% chance BSX will rise after recent bearish signals.
- Forward distribution projects BSX could reach $59–$64 in 10 weeks, peaking near $62.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →